GNLX trades 484.5% below Wall Street's consensus target of $17.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes GNLX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, Genelux Corporation (GNLX) has a Wall Street consensus price target of $17.33, based on estimates from 3 covering analysts. With the stock currently trading at $2.96, this represents a potential upside of +484.5%. The company has a market capitalization of $112M.
Analyst price targets range from a low of $16.00 to a high of $20.00, representing a 23% spread in expectations. The median target of $16.00 differs from the mean, suggesting potential outlier estimates. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, GNLX trades at a trailing P/E of -3.4x. Analysts expect EPS to grow +16.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
IMVTImmunovant, Inc. | $7.3B | $35.34 | $45.00 | +27.3% | Buy | — | 23 |
TGTXTG Therapeutics, Inc. | $8.1B | $53.22 | $54.50 | +2.4% | Buy | 38.6x | 13 |
KRYSKrystal Biotech, Inc. | $10.3B | $348.06 | $336.40 | -3.4% | Buy | 44.9x | 17 |
ADCTADC Therapeutics S.A. | $139M | $1.09 | $3.50 | +221.1% | Hold | — | 12 |
VVOSVivos Therapeutics, Inc. | $3M | $0.50 | — | — | — | — | — |
IMCRImmunocore Holdings plc | $1.5B | $28.60 | $46.50 | +62.6% | Buy | 239.5x | 14 |
CLDXCelldex Therapeutics, Inc. | $2.2B | $32.43 | $49.00 | +51.1% | Buy | — | 19 |
NKTRNektar Therapeutics | $1.2B | $60.98 | $149.60 | +145.3% | Buy | — | 33 |
AGENAgenus Inc. | $125M | $3.00 | $7.33 | +144.3% | Buy | 3.8x | 11 |
SNDXSyndax Pharmaceuticals, Inc. | $1.7B | $19.00 | $38.50 | +102.6% | Buy | — | 22 |
Quick answers to the most common questions about buying GNLX stock.
The consensus Wall Street price target for GNLX is $17.33, representing 484.5% upside from the current price of $2.965. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
GNLX has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $17.33 implies 484.5% upside from current levels.
GNLX's current price is $2.965 with a consensus target of $17.33 (484.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $20 for GNLX, while the most conservative target is $16. The consensus of $17.33 represents the median expectation. These targets typically reflect 12-month expectations.
GNLX is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GNLX stock forecast based on 3 Wall Street analysts shows a consensus price target of $17.33, with estimates ranging from $16 (bear case) to $20 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on GNLX, with a "Buy" consensus rating and $17.33 price target (484.5% upside). 2 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GNLX analyst price targets range from $16 to $20, a 23% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $17.33 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.